International Urology and Nephrology

, Volume 46, Issue 12, pp 2279–2283 | Cite as

Efficacy of tamsulosin hydrochloride in relieving “double-J ureteral stent-related morbidity”: a randomized placebo controlled clinical study

  • Iqbal SinghEmail author
  • Sambit Tripathy
  • Vivek Agrawal
Urology – Original Paper



To evaluate the efficacy of tamsulosin therapy in reducing ureteral double-J stent morbidity by evaluating USSQ, IPSS, QOL and VAS (primary objective) and to evaluate the morbidity and or complication(s) associated with indwelling double-J ureteral stent(s) and to evaluate the safety of tamsulosin therapy for “morbidity associated with double-J stents” by evaluating its tolerability, side effects and adverse events if any (secondary objective) as per protocol.


After institutional review board approval, 60 consecutive patients with a double-J ureteral stent inserted after percutaneous nephrolithotomy or ureteroscopic stone treatment were randomly assigned to receive tamsulosin 0.4 mg, or a placebo for 4 weeks. The validated USSQ, VAS and IPSS were completed before stent insertion, at 3 days and 4 weeks after stent insertion and at 2 weeks after stent removal. Data were statistically analyzed for efficacy and tolerability of one drug over the other using Wilcoxon signed-rank test, Mann–Whitney test and Student’s t test.


Patients receiving tamsulosin compared with the placebo showed significant decrease in urinary index score, pain index score, work performance score, VAS score at loin area, VAS score at flank, VAS score at suprapubic area, average VAS score, need for antibiotics, number of hospital visits (P < 0.05) at the end of fourth weeks. Decrease in values were also observed in IPSS score, general health score, quality of sex score and IPSS-quality of life (QOL) score in patients taking tamsulosin but, however, the decrease was not significant. No patients discontinued medication because of side effects.


We conclude that ureteral stenting using double-J stents with concomitant tamsulosin therapy was generally well tolerated, safe, effective and significantly beneficial in reducing stent morbidity in the majority of our patients. We advocate the routine use of concomitant tamsulosin therapy in eligible patients undergoing ureteral stenting in order to minimize stent morbidity.


Tamsulosin Ureteral stent morbidity JJ stent USSQ 


Conflict of interest

The authors declare that “we have no conflict of interest” in the publication of the above manuscript.


  1. 1.
    Gerber GS, Lyon ES (1993) Endourological management of upper tract urothelial tumors. J Urol 150:2PubMedGoogle Scholar
  2. 2.
    Leventhal EK, Rozanski TA, Crain TW, Deshon GE (1995) Indwelling ureteral stents as definitive therapy for distal ureteral calculi. J Urol 153:34–36PubMedCrossRefGoogle Scholar
  3. 3.
    Joshi HB, Okeke A, Newns N, Keely FX, Timoney AG (2002) Characterization of urinary symptoms in patients with ureteral stents. Urology 59(4):511–516PubMedCrossRefGoogle Scholar
  4. 4.
    Singh I, Gupta NP, Hemal AK, Aron M, Seth A, Dogra PN (2001) Severely encrusted polyurethane ureteral stents: management and analysis of potential risk factors. Urology 58(4):526–531PubMedCrossRefGoogle Scholar
  5. 5.
    Menon AN, Talpur AA, Menon JM (2007) Indication and complications of indwelling ureteral stenting at NMCH. Nawabshah. Pak J Surg 3:187–191Google Scholar
  6. 6.
    Singh I (2003) Indwelling ureteral JJ stent: a current perspective and review of literature. Ind J Surg 65:405–412Google Scholar
  7. 7.
    Joshi HB, Stainthorpe A, Macdonagh RP et al (2003) Indwelling ureteral stents: evaluation of symptoms, quality of life and utility. J Urol 169:1065–1069PubMedCrossRefGoogle Scholar
  8. 8.
    Deliveliotis C, Chrisofos M, Gougousis E et al (2006) Is there a role for alpha-1 blockers in treating double-j stent-related symptoms? Urology 67:35–39PubMedCrossRefGoogle Scholar
  9. 9.
    Damiano R, Autorino R, De Sio M et al (2008) Effect of tamsulosin in preventing ureteral stent related morbidity: a prospective study. J Endourol 22:651–656PubMedCrossRefGoogle Scholar
  10. 10.
    Beddingfield R, Pedro RN, Hinck B et al (2009) Alfuzosin to relieve ureteral stent discomfort: a prospective, randomized, placebo controlled study. J Urol 181:170–176PubMedCrossRefGoogle Scholar
  11. 11.
    Nazim SM, Ather MH (2012) Alpha-blockers impact stent- related symptoms : a randomized, double-blind, placebo-controlled trial. J Endourol 26(9):1237–1241PubMedCrossRefGoogle Scholar
  12. 12.
    Wang CJ, Huang SW, Chang CH (2009) effects of tamsulosin on lower urinary tract symptoms due to double-J stent: a prospective study. Urol Int 83:66–69PubMedCrossRefGoogle Scholar
  13. 13.
    Wang CJ, Huang SW, Chang CH (2009) Effects of specific alpha-1A/1D blocker on lower urinary tract symptoms due to double-J stent: a prospectively randomized study. Urol Res 37(3):147–152PubMedCrossRefGoogle Scholar
  14. 14.
    Lamb AD, Vowler SL, Johnston R et al (2011) Meta-analysis showing the beneficial effect of alpha blockers on ureteric stent discomfort. BJU Int 108:1894–1902PubMedCrossRefGoogle Scholar
  15. 15.
    Yakoubi R, Lemdani M, Monga M et al (2011) Is there a role for α-blockers in ureteral stent related symptoms? A systematic review and meta-analysis. J Urol 186(3):928–934PubMedCrossRefGoogle Scholar
  16. 16.
    Dellis AE, Keeley FX Jr, Manolas V, Skolarikos AA (2014) Role of α-blockers in the treatment of stent-related symptoms: a prospective randomized control study. Urology. 83(1):56–61PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2014

Authors and Affiliations

  1. 1.Department of SurgeryUniversity College of Medical Sciences (University of Delhi) & GTB HospitalDelhiIndia

Personalised recommendations